Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Chronic Kidney Disease (CKD) Market Gains Momentum as Pipeline Innovation and Clinical Trials Reshape the Competitive Landscape in 2026

globenewswire.com
AZN AstraZeneca's drug Farxiga is approved for CKD and AZD4248 is in early development. The article mentions both marketed and investigational drugs. LLY Eli Lilly's drug Jardiance (co-developed with Boehringer Ingelheim) is approved for CKD. The article mentions Jardiance and its CKD indication. REGN Regeneron Pharmaceuticals is listed as a key player in the CKD market. The article mentions REGN5459 as a product candidate. IONS Ionis Pharmaceuticals is listed as a key player in the CKD market. The article mentions ION532 as a product candidate. MRK Merck Sharp & Dohme is listed as a key player in the CKD market. The article mentions MK-2060 as a product candidate. XRTX XORTX Therapeutics is listed as a key player in the CKD market. The article mentions XRx-008 as a product candidate. DMAC DiaMedica Therapeutics is listed as a key player in the CKD market. The article mentions DM199 as a product candidate. LSTA Lisata Therapeutics is listed as a key player in the CKD market. The article mentions FT011 as a product candidate.

Chronic Kidney Disease (CKD) Market Gains Momentum as Pipeline Innovation and Clinical Trials Reshape the Competitive Landscape in 2026 Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- "Chronic Kidney Disease - Competitive Landscape and Clinical Trial Analysis, 2026" has been added to ResearchAndMarkets.com's offering.

The report provides a comprehensive assessment of more than 90 companies and over 100 marketed and investigational drugs within the global chronic kidney disease market. The report evaluates therapies by development stage, product type, molecule type, route of administration, clinical status, and therapeutic technology. It also examines inactive pipeline products, unmet medical needs, commercial agreements, and emerging trends influencing chronic kidney disease drug development.

Recent Chronic Kidney Disease Pipeline and Market Developments

Marketed Chronic Kidney Disease Therapies

Farxiga (dapagliflozin) - AstraZeneca: Farxiga is an oral sodium-glucose cotransporter 2 inhibitor approved by the FDA for chronic kidney disease on April 30, 2021. It is indicated to reduce the risks of sustained estimated glomerular filtration rate decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with CKD at risk of progression.

Jardiance (empagliflozin) - Boehringer Ingelheim and Eli Lilly: Jardiance is an oral sodium-glucose cotransporter 2 inhibitor approved for its CKD indication on September 22, 2023. The therapy is indicated to reduce sustained renal function decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease at risk of progression.

Kerendia (finerenone) - Bayer: Kerendia is an oral, non-steroidal mineralocorticoid receptor antagonist approved on July 9, 2021, for chronic kidney disease associated with type 2 diabetes. It is indicated to reduce the risks of sustained eGFR decline, end-stage kidney disease, cardiovascular death, nonfatal myocardial infarction, and hospitalization for heart failure.

Selected Chronic Kidney Disease Pipeline Therapies

HRS-1780 - Jiangsu Hengrui Pharmaceuticals: HRS-1780 is a selective, non-steroidal mineralocorticoid receptor antagonist in Phase III development for chronic kidney disease. Phase II findings showed dose-dependent reductions in urinary albumin-to-creatinine ratio. Its Phase III program is evaluating efficacy and safety when administered with standard treatment.

Vicadrostat (BI 690517) - Boehringer Ingelheim: Vicadrostat is a selective aldosterone synthase inhibitor designed to reduce aldosterone-associated inflammation, fibrosis, albuminuria, and cardiorenal damage. It is being evaluated with empagliflozin in the Phase III EASi-KIDNEY clinical trial for patients at risk of CKD progression.

NNC0519-0130 - Novo Nordisk: NNC0519-0130 is an investigational once-weekly subcutaneous GLP-1 and GIP receptor dual agonist. A Phase II proof-of-concept and dose-finding study is comparing multiple doses with semaglutide and placebo in approximately 465 participants while assessing efficacy, safety, pharmacokinetics, and renal outcomes.

IGT-303 - Ingenia Therapeutics: IGT-303 is a TIE2-targeted therapy in Phase I/IIa development for chronic kidney disease, including diabetic kidney disease. The program is assessing safety, tolerability, pharmacokinetics, and potential effects on endothelial dysfunction and renal disease progression.

AZD4248 - AstraZeneca: AZD4248 is an investigational small-molecule nicotinamide N-methyltransferase inhibitor in Phase I development for cardiorenal disease. The first-in-human trial includes healthy participants and patients with chronic kidney disease and type 2 diabetes.

Commercial and Competitive Analysis

The report provides an in-depth commercial assessment of chronic kidney disease companies and therapies, including licensing agreements, strategic collaborations, acquisitions, research partnerships, and transaction value trends. Company-to-company partnerships, industry-academic collaborations, and acquisition activity are presented in structured comparative formats.

The chronic kidney disease competitive landscape analysis compares companies by therapeutic approach, development stage, technology, molecule type, and clinical progress. The report also evaluates marketed therapies, emerging drugs, inactive assets, unmet needs, and opportunities for differentiated treatment strategies.

Clinical Trial Analysis

Key Questions Addressed

Selected Key Players

AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly and Company, Novo Nordisk, Roche, Regeneron Pharmaceuticals, Ionis Pharmaceuticals, Merck Sharp & Dohme, ProKidney, KBP Biosciences, XORTX Therapeutics, DiaMedica Therapeutics, Galapagos NV, SCOHIA PHARMA, Sentien Biotechnologies, Lisata Therapeutics, Disc Medicine, Pharmicell, OccuRx, Kibow Pharma, and Shandong Suncadia Medicine are among the companies covered.

Selected Key Products

Products and candidates evaluated include empagliflozin, dapagliflozin, finerenone, semaglutide, bardoxolone methyl, ziltivekimab, KBP-5074, XRx-008, zibotentan, pirfenidone, verinurad, AZD9977, ALLN-346, BI 690517, BI-685509, BI 764198, SCO-792, DM199, baxdrostat, GLPG2737, runcaciguat, SBI-101, REGN5459, ELIXCYTE, FT011, Cellgram-CKD, CLBS201, BAY3283142, ION532, and MK-2060.

The report offers a detailed resource for pharmaceutical companies, biotechnology developers, investors, researchers, healthcare strategists, and other stakeholders seeking actionable intelligence on the chronic kidney disease market, competitive environment, clinical trial landscape, and emerging treatment pipeline.

A selection of companies mentioned in this report includes, but is not limited to:

For more information about this report visit https://www.researchandmarkets.com/r/b6w55f

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.